NO20021329L - Kinaseinhibitorer som terapeutiske midler - Google Patents

Kinaseinhibitorer som terapeutiske midler

Info

Publication number: NO20021329L
Authority: NO; Norway
Prior art keywords: therapeutic agents; kinase inhibitors; kinase; inhibitors; therapeutic
Prior art date: 1999-09-17

Application number

NO20021329A

Other languages

English (en)

Other versions

NO20021329D0 (no

Inventor

Gavin C Hirst

Paul Rafferty

David Calderwood

Helen Louise Twigger

Stephen St Gallay

Kurt Ritter

Original Assignee

Abbott Gmbh & Co Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-17

Filing date

2002-03-18

Publication date

2002-05-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22552056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20021329(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-03-18 Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg

2002-03-18 Publication of NO20021329D0 publication Critical patent/NO20021329D0/no

2002-05-21 Publication of NO20021329L publication Critical patent/NO20021329L/no

Links

239000003814 drug Substances 0.000 title 1
229940043355 kinase inhibitor Drugs 0.000 title 1
239000003757 phosphotransferase inhibitor Substances 0.000 title 1
229940124597 therapeutic agent Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Virology (AREA)
Oncology (AREA)
Hematology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Tropical Medicine & Parasitology (AREA)
Biochemistry (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
AIDS & HIV (AREA)
Reproductive Health (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20021329A 1999-09-17 2002-03-18 Kinaseinhibitorer som terapeutiske midler NO20021329L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15461899P	1999-09-17	1999-09-17
PCT/US2000/025357 WO2001019828A2 (en)	1999-09-17	2000-09-15	Kinase inhibitors as therapeutic agents

Publications (2)

Publication Number	Publication Date
NO20021329D0 NO20021329D0 (no)	2002-03-18
NO20021329L true NO20021329L (no)	2002-05-21

Family

ID=22552056

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20021329A NO20021329L (no)	1999-09-17	2002-03-18	Kinaseinhibitorer som terapeutiske midler

Country Status (27)

Country	Link
EP (1)	EP1268481B1 (no)
JP (1)	JP2003509427A (no)
KR (1)	KR20020063854A (no)
CN (1)	CN1390220A (no)
AR (1)	AR029766A1 (no)
AT (1)	ATE380814T1 (no)
AU (1)	AU7491400A (no)
BG (1)	BG106585A (no)
BR (1)	BR0014075A (no)
CA (1)	CA2385769A1 (no)
CY (1)	CY1107886T1 (no)
CZ (1)	CZ2002934A3 (no)
DE (1)	DE60037455T2 (no)
DK (1)	DK1268481T3 (no)
ES (1)	ES2299434T3 (no)
HK (1)	HK1053831A1 (no)
HU (1)	HUP0303363A2 (no)
IL (1)	IL148719A0 (no)
MX (1)	MXPA02002938A (no)
NO (1)	NO20021329L (no)
NZ (1)	NZ517759A (no)
PL (1)	PL354241A1 (no)
PT (1)	PT1268481E (no)
SK (1)	SK3792002A3 (no)
TR (1)	TR200201506T2 (no)
WO (1)	WO2001019828A2 (no)
ZA (1)	ZA200202122B (no)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7235551B2 (en)	2000-03-02	2007-06-26	Smithkline Beecham Corporation	1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
CN100525768C (zh)	2000-10-23	2009-08-12	史密丝克莱恩比彻姆公司	新化合物
AU2002333524A1 (en)	2001-09-11	2003-03-24	Glaxosmithkline K.K.	Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
CA2477117A1 (en) *	2002-02-22	2003-08-28	Teijin Limited	Pyrrolopyrimidine derivative
US7560552B2 (en)	2002-03-21	2009-07-14	Abbott Laboratories	Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
US20030225273A1 (en) *	2002-03-21	2003-12-04	Michaelides Michael R.	Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
KR20040103972A (ko)	2002-04-19	2004-12-09	스미스클라인 비참 코포레이션	신규 화합물
DE60304718T2 (de)	2002-08-06	2007-04-26	Astrazeneca Ab	Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
WO2004100947A2 (en)	2003-05-06	2004-11-25	Smithkline Beecham Corporation	Novel chemical compounds
US7297709B2 (en)	2003-05-22	2007-11-20	Abbott Laboratories	Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US7129260B2 (en)	2003-06-02	2006-10-31	Abbott Laboratories	Isoindolinone kinase inhibitors
US7202363B2 (en)	2003-07-24	2007-04-10	Abbott Laboratories	Thienopyridine and furopyridine kinase inhibitors
US20050026944A1 (en) *	2003-07-24	2005-02-03	Patrick Betschmann	Thienopyridine and furopyridine kinase inhibitors
WO2005011597A2 (en) *	2003-07-29	2005-02-10	Irm Llc	Compounds and compositions as protein kinase inhibitors
AU2004309420B2 (en) *	2003-12-23	2008-10-30	Novartis Ag	Bicyclic heterocyclic p-38 kinase inhibitors
TW200530236A (en) *	2004-02-23	2005-09-16	Chugai Pharmaceutical Co Ltd	Heteroaryl phenylurea
WO2005111001A1 (en) *	2004-05-19	2005-11-24	Astrazeneca Ab	Novel fused heterocycles and uses thereof
FR2871158A1 (fr)	2004-06-04	2005-12-09	Aventis Pharma Sa	Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
US20070054916A1 (en) *	2004-10-01	2007-03-08	Amgen Inc.	Aryl nitrogen-containing bicyclic compounds and methods of use
ATE554087T1 (de)	2004-10-29	2012-05-15	Abbott Lab	Neue kinaseinhibitoren
DE102004061288A1 (de) *	2004-12-14	2006-06-29	Schering Ag	3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
PE20061119A1 (es)	2005-01-19	2006-11-27	Aventis Pharma Sa	PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
EP1683796A1 (en) *	2005-01-24	2006-07-26	Schering Aktiengesellschaft	Pyrazolopyridines, their preparation and their medical use
US7842809B2 (en)	2005-01-24	2010-11-30	Bayer Schering Pharma Ag	Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same
PE20061193A1 (es)	2005-03-25	2006-12-02	Glaxo Group Ltd	DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
MY145343A (en)	2005-03-25	2012-01-31	Glaxo Group Ltd	Novel compounds
US7423042B2 (en)	2005-03-25	2008-09-09	Glaxo Group Limited	Compounds
US20080096905A1 (en)	2005-03-25	2008-04-24	Glaxo Group Limited	Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
US7884109B2 (en)	2005-04-05	2011-02-08	Wyeth Llc	Purine and imidazopyridine derivatives for immunosuppression
US7795248B2 (en) *	2005-05-18	2010-09-14	Abbott Laboratories, Inc.	Substituted 7,8-dihydro-1H-pyrimido[4,5-B][1,4]diazepin-4-amines are novel kinase inhibitors
FR2889526B1 (fr) *	2005-08-04	2012-02-17	Aventis Pharma Sa	7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
DE102005042742A1 (de) *	2005-09-02	2007-03-08	Schering Ag	Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
KR20080045279A (ko) *	2005-09-14	2008-05-22	얀센 파마슈티카 엔.브이.	Ｃ-ｆｍｓ 키나제 저해제로서의5-옥소-5,8-디하이드로-피리도-피리미딘
TW200800983A (en) *	2005-09-14	2008-01-01	Janssen Pharmaceutica Nv	5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
ES2365869T3 (es)	2005-11-17	2011-10-11	OSI Pharmaceuticals, LLC	COMPUESTOS BICÍCLICOS FUSIONADOS INHIBIDORES DE LA mTOR.
PE20070855A1 (es) *	2005-12-02	2007-10-14	Bayer Pharmaceuticals Corp	Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
WO2007064931A2 (en) *	2005-12-02	2007-06-07	Bayer Healthcare Llc	Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TW200738725A (en) *	2006-01-25	2007-10-16	Osi Pharm Inc	Unsaturated mTOR inhibitors
US7622463B2 (en) *	2006-02-14	2009-11-24	Vertex Pharmaceuticals Incorporated	Dihydrodiazepines useful as inhibitors of protein kinases
US7989459B2 (en)	2006-02-17	2011-08-02	Pharmacopeia, Llc	Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
JP2009527459A (ja) *	2006-02-23	2009-07-30	武田薬品工業株式会社	縮合窒素含有複素環化合物
TW200815437A (en) *	2006-06-13	2008-04-01	Bayer Schering Pharma Ag	Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
WO2008022060A2 (en) *	2006-08-14	2008-02-21	Novartis Ag	Imidazo-pyridine derivatives for modulating protein kinase activity
US7897762B2 (en)	2006-09-14	2011-03-01	Deciphera Pharmaceuticals, Llc	Kinase inhibitors useful for the treatment of proliferative diseases
TW200837064A (en)	2006-10-04	2008-09-16	Pharmacopeia Inc	8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
US7919490B2 (en)	2006-10-04	2011-04-05	Wyeth Llc	6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7902187B2 (en)	2006-10-04	2011-03-08	Wyeth Llc	6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
AU2008228303B2 (en) *	2007-03-22	2012-04-19	Takeda Pharmaceutical Company Limited	Substituted pyrimidodiazepines useful as PLK1 inhibitors
JP2010527999A (ja)	2007-05-23	2010-08-19	フアーマコペイア・エル・エル・シー	ＰＫＣ−θ阻害剤としてのプリノン類および１Ｈ−イミダゾピリジノン類
DE102007024470A1 (de)	2007-05-24	2008-11-27	Bayer Schering Pharma Aktiengesellschaft	Neue Sulfoximin-substituierte Chinolin- bzw. Chinazolinderivate als Kinase-Inhibitoren
EP2205241B1 (en)	2007-09-25	2014-05-21	Takeda Pharmaceutical Company Limited	Polo-like kinase inhibitors
EP2072502A1 (de)	2007-12-20	2009-06-24	Bayer Schering Pharma Aktiengesellschaft	Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren
CN101239978A (zh) *	2008-03-05	2008-08-13	南方医科大学	一种咪唑并吡啶类化合物
US20100048913A1 (en)	2008-03-14	2010-02-25	Angela Brodie	Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
CA2719134C (en)	2008-03-21	2015-06-30	The University Of Chicago	Treatment with opioid antagonists and mtor inhibitors
EP2303889A1 (en)	2008-06-18	2011-04-06	F. Hoffmann-La Roche AG	Halo-substituted pyrimidodiazepines as plkl inhibitors
CN102239171B (zh)	2008-12-05	2014-06-11	艾伯维巴哈马有限公司	作为激酶抑制剂用于治疗癌症的噻吩并[3,2-c]吡啶衍生物
CN102686600A (zh)	2009-02-05	2012-09-19	托凯药业股份有限公司	甾体cyp17抑制剂/抗雄激素物质的新型药物前体
US8846673B2 (en)	2009-08-11	2014-09-30	Bristol-Myers Squibb Company	Azaindazoles as kinase inhibitors and use thereof
CN103492391A (zh)	2009-09-25	2014-01-01	沃泰克斯药物股份有限公司	用于制备用作蛋白激酶抑制剂的嘧啶衍生物的方法
CN102548994A (zh)	2009-09-25	2012-07-04	沃泰克斯药物股份有限公司	用于制备用作蛋白激酶抑制剂的嘧啶衍生物的方法
JP5764145B2 (ja) *	2010-02-08	2015-08-12	メルク・シャープ・エンド・ドーム・ベー・フェー	８−メチル−１−フェニル−イミダゾル［１，５−ａ］ピラジン化合物
AU2015202128B2 (en) *	2010-05-31	2015-05-28	Ono Pharmaceutical Co., Ltd.	Purinone derivative
TWI500617B (zh) *	2010-05-31	2015-09-21	Ono Pharmaceutical Co	Purine ketone derivatives
EP2548877A1 (en)	2011-07-19	2013-01-23	MSD Oss B.V.	4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
EP3689878B1 (en)	2011-07-19	2021-10-06	Merck Sharp & Dohme B.V.	4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
US8436179B2 (en)	2011-07-20	2013-05-07	Abbvie Inc.	Kinase inhibitor with improved solubility profile
US9199997B2 (en)	2011-11-29	2015-12-01	Ono Pharmaceutical Co., Ltd.	Purinone derivative hydrochloride
UY34484A (es)	2011-12-15	2013-07-31	Bayer Ip Gmbh	Benzotienilo-pirrolotriazinas disustituidas y sus usos
CN104159900B (zh)	2011-12-15	2016-08-24	拜耳知识产权有限责任公司	取代的苯并噻吩基-吡咯并三嗪及其在癌症治疗中的用途
US8501724B1 (en) *	2012-01-31	2013-08-06	Pharmacyclics, Inc.	Purinone compounds as kinase inhibitors
JP6082033B2 (ja)	2012-02-23	2017-02-15	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	置換ベンゾチエニル−ピロロトリアジンおよびその使用
WO2013177668A1 (en)	2012-05-31	2013-12-05	Pharmascience, Inc.	Protein kinase inhibitors
CA2782774A1 (en) *	2012-07-06	2014-01-06	Pharmascience Inc.	Protein kinase inhibitors
CN103655566B (zh) *	2012-09-10	2016-12-21	杨子娇	化合物在制备防治青光眼病的药物中的用途
CN105796569A (zh) *	2012-09-10	2016-07-27	杨子娇	化合物在制备防治青光眼病的药物中的用途
US20140206681A1 (en)	2013-01-23	2014-07-24	Ronald M. Kim	Btk inhibitors
WO2014113942A1 (en)	2013-01-23	2014-07-31	Merck Sharp & Dohme Corp.	Btk inhibitors
RU2015137617A (ru)	2013-03-14	2017-04-18	Юниверсити Оф Мэриленд, Балтимор Офис Оф Текнолоджи Трансфер	Агенты, подавляющие андрогенные рецепторы, и их применение
WO2015002894A1 (en) *	2013-07-02	2015-01-08	Pharmacyclics, Inc.	Purinone compounds as kinase inhibitors
CN105636594A (zh)	2013-08-12	2016-06-01	托凯药业股份有限公司	使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
CA2833701A1 (en) *	2013-11-19	2015-05-19	Pharmascience Inc.	Protein kinase inhibitors
CA2833867A1 (en) *	2013-11-21	2015-05-21	Pharmascience Inc.	Protein kinase inhibitors
CN105979948A (zh)	2013-12-05	2016-09-28	安塞塔制药公司	Pi3k抑制剂和btk抑制剂的治疗组合
US9834554B2 (en)	2013-12-20	2017-12-05	Merck Sharp & Dohme Corp.	BTK inhibitors
WO2015095099A1 (en)	2013-12-20	2015-06-25	Merck Sharp & Dohme Corp.	Btk inhibitors
CA2935167C (en)	2014-01-16	2022-02-22	Musc Foundation For Research Development	Targeted nanocarriers for the administration of immunosuppressive agents
US10272083B2 (en)	2014-01-21	2019-04-30	Acerta Pharma B.V.	Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
WO2015146159A1 (en)	2014-03-25	2015-10-01	Ono Pharmaceutical Co., Ltd.	Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma
US9937171B2 (en)	2014-04-11	2018-04-10	Acerta Pharma B.V.	Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
US9949971B2 (en)	2014-06-17	2018-04-24	Acerta Pharma B.V.	Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor
PL3179991T3 (pl)	2014-08-11	2022-02-14	Acerta Pharma B.V.	Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2
WO2016106626A1 (en)	2014-12-31	2016-07-07	Merck Sharp & Dohme Corp.	Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors
WO2016106629A1 (en)	2014-12-31	2016-07-07	Merck Sharp & Dohme Corp.	Btk inhibitors
WO2016106624A1 (en)	2014-12-31	2016-07-07	Merck Sharp & Dohme Corp.	Tertiary alcohol imidazopyrazine btk inhibitors
WO2016106623A1 (en)	2014-12-31	2016-07-07	Merck Sharp & Dohme Corp.	Benzamide imidazopyrazine btk inhibitors
WO2016106628A1 (en)	2014-12-31	2016-07-07	Merck Sharp & Dohme Corp.	Btk inhibitors
ES2955554T3 (es)	2015-04-09	2023-12-04	Ono Pharmaceutical Co	Proceso para producir un derivado de purinona
HUE062258T2 (hu)	2015-07-02	2023-10-28	Acerta Pharma Bv	(S)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-N-(piridin-2-il)benzamid szilárd alakjai és készítményei
CN105130932B (zh) *	2015-07-14	2017-06-16	中国科学院微生物研究所	化合物及其在制备ptp1b抑制剂和治疗和/或预防ⅱ型糖尿病的药物的用途
WO2017035366A1 (en)	2015-08-26	2017-03-02	Incyte Corporation	Pyrrolopyrimidine derivatives as tam inhibitors
KR102483020B1 (ko)	2016-03-28	2023-01-04	인사이트 코포레이션	Tam 저해제로서의 피롤로트리아진 화합물
CN115819417A (zh)	2016-09-09	2023-03-21	因赛特公司	作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途
WO2018049214A1 (en)	2016-09-09	2018-03-15	Incyte Corporation	Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
US10280164B2 (en)	2016-09-09	2019-05-07	Incyte Corporation	Pyrazolopyridone compounds and uses thereof
US20180072741A1 (en)	2016-09-09	2018-03-15	Incyte Corporation	Pyrazolopyrimidine compounds and uses thereof
WO2018152220A1 (en)	2017-02-15	2018-08-23	Incyte Corporation	Pyrazolopyridine compounds and uses thereof
US10722495B2 (en)	2017-09-08	2020-07-28	Incyte Corporation	Cyanoindazole compounds and uses thereof
MA50655B1 (fr)	2017-09-27	2021-11-30	Incyte Corp	Sels de dérivés de pyrrolotriazine utiles en tant qu'inhibiteurs de tam
EP3755703B1 (en)	2018-02-20	2022-05-04	Incyte Corporation	N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer
US10752635B2 (en)	2018-02-20	2020-08-25	Incyte Corporation	Indazole compounds and uses thereof
US10745388B2 (en)	2018-02-20	2020-08-18	Incyte Corporation	Indazole compounds and uses thereof
US11299473B2 (en)	2018-04-13	2022-04-12	Incyte Corporation	Benzimidazole and indole compounds and uses thereof
AR117600A1 (es)	2018-06-29	2021-08-18	Incyte Corp	Formulaciones de un inhibidor de axl / mer
US10899755B2 (en)	2018-08-08	2021-01-26	Incyte Corporation	Benzothiazole compounds and uses thereof
WO2020068729A1 (en)	2018-09-25	2020-04-02	Incyte Corporation	Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators
BR112022002059A2 (pt)	2019-08-06	2022-06-07	Incyte Corp	Formas sólidas de um inibidor de hpk1
WO2021178779A1 (en)	2020-03-06	2021-09-10	Incyte Corporation	Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
WO2024240088A1 (en) *	2023-05-19	2024-11-28	Chengdu Anticancer Bioscience , Ltd.	Compounds, compositions and methods of treating disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TR199902301T2 (xx) *	1997-03-19	1999-12-21	Basf Aktiengesellschaft	Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
UA71945C2 (en) *	1999-01-27	2005-01-17	Pfizer Prod Inc	Substituted bicyclic derivatives being used as anticancer agents

2000
- 2000-09-15 MX MXPA02002938A patent/MXPA02002938A/es unknown
- 2000-09-15 DE DE60037455T patent/DE60037455T2/de not_active Expired - Lifetime
- 2000-09-15 CN CN00815776A patent/CN1390220A/zh active Pending
- 2000-09-15 DK DK00963510T patent/DK1268481T3/da active
- 2000-09-15 AT AT00963510T patent/ATE380814T1/de active
- 2000-09-15 SK SK379-2002A patent/SK3792002A3/sk unknown
- 2000-09-15 PL PL00354241A patent/PL354241A1/xx not_active Application Discontinuation
- 2000-09-15 HK HK03104425.4A patent/HK1053831A1/zh unknown
- 2000-09-15 TR TR2002/01506T patent/TR200201506T2/xx unknown
- 2000-09-15 WO PCT/US2000/025357 patent/WO2001019828A2/en not_active Ceased
- 2000-09-15 HU HU0303363A patent/HUP0303363A2/hu unknown
- 2000-09-15 NZ NZ517759A patent/NZ517759A/en unknown
- 2000-09-15 CZ CZ2002934A patent/CZ2002934A3/cs unknown
- 2000-09-15 CA CA002385769A patent/CA2385769A1/en not_active Abandoned
- 2000-09-15 EP EP00963510A patent/EP1268481B1/en not_active Expired - Lifetime
- 2000-09-15 BR BR0014075-9A patent/BR0014075A/pt not_active IP Right Cessation
- 2000-09-15 JP JP2001523405A patent/JP2003509427A/ja not_active Withdrawn
- 2000-09-15 AU AU74914/00A patent/AU7491400A/en not_active Abandoned
- 2000-09-15 KR KR1020027003507A patent/KR20020063854A/ko not_active Withdrawn
- 2000-09-15 IL IL14871900A patent/IL148719A0/xx unknown
- 2000-09-15 PT PT00963510T patent/PT1268481E/pt unknown
- 2000-09-15 ES ES00963510T patent/ES2299434T3/es not_active Expired - Lifetime
- 2000-09-18 AR ARP000104887A patent/AR029766A1/es unknown
2002
- 2002-03-14 ZA ZA200202122A patent/ZA200202122B/en unknown
- 2002-03-18 NO NO20021329A patent/NO20021329L/no not_active Application Discontinuation
- 2002-04-05 BG BG106585A patent/BG106585A/xx unknown
2008
- 2008-02-14 CY CY20081100173T patent/CY1107886T1/el unknown

Also Published As

Publication number	Publication date
IL148719A0 (en)	2002-09-12
JP2003509427A (ja)	2003-03-11
NZ517759A (en)	2004-04-30
PL354241A1 (en)	2003-12-29
DE60037455D1 (de)	2008-01-24
EP1268481B1 (en)	2007-12-12
DK1268481T3 (da)	2008-05-05
HUP0303363A2 (hu)	2004-07-28
HK1053831A1 (zh)	2003-11-07
PT1268481E (pt)	2008-03-19
KR20020063854A (ko)	2002-08-05
CY1107886T1 (el)	2013-06-19
NO20021329D0 (no)	2002-03-18
AU7491400A (en)	2001-04-17
CZ2002934A3 (cs)	2002-07-17
BG106585A (en)	2003-03-31
DE60037455T2 (de)	2008-11-27
EP1268481A2 (en)	2003-01-02
MXPA02002938A (es)	2004-12-06
CN1390220A (zh)	2003-01-08
TR200201506T2 (tr)	2002-10-21
BR0014075A (pt)	2002-07-16
CA2385769A1 (en)	2001-03-22
SK3792002A3 (en)	2003-09-11
ZA200202122B (en)	2003-08-27
WO2001019828A3 (en)	2001-10-04
WO2001019828A2 (en)	2001-03-22
ATE380814T1 (de)	2007-12-15
ES2299434T3 (es)	2008-06-01
AR029766A1 (es)	2003-07-16

Legal Events

Date	Code	Title	Description
2005-01-17	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20021329D0 (no)	2002-03-18	Kinaseinhibitorer som terapeutiske midler
NO20021239D0 (no)	2002-03-13	Pteridinoner som kinase-inhibitorer
PT1226136E (pt)	2005-04-29	Inibidores da tirosina quinase
NO20021328D0 (no)	2002-03-18	Pyrazolopyrimidiner som terapeutiske midler
NO20023828L (no)	2002-09-30	Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer
DK1140840T3 (da)	2006-07-31	omega-carboxyaryl-substituerede diphenylurinstoffer som raf-kinase-inhibitorer
DK1244647T3 (da)	2006-09-25	Quinzolinderivater som VIGF-inhibitorer
ATE318603T1 (de)	2006-03-15	Pyrrolotriazin kinasehemmer
NO20015065L (no)	2001-10-18	Pyrazolobenzodiazepiner som CDK2-inhibitorer
EP1296697A4 (en)	2005-02-16	Therapeutic agents - i
NO20031006L (no)	2003-03-04	Imidazolo-5-yl-2-anilino-pyrimidiner som midler for inhibering av celleproliferasjon
NO20021400D0 (no)	2002-03-20	Terapeutiske konazolinderivater
NO20034176L (no)	2003-11-21	Pyrazolopyrimidiner som terapeutiske midler
NO20034177D0 (no)	2003-09-19	Pyrazolopyrimidiner som terapeutiske midler
DK1337527T3 (da)	2010-01-04	Indolylmaleinimidderivater som proteinkinase C-inhibitorer
DE60002193D1 (de)	2003-05-22	Metalloprotease inhibitoren
ID30460A (id)	2001-12-06	Inhibitor-inhibitor protein siklik tirosin kinase
NO20022692L (no)	2002-08-07	Terapeutiske midler
NO20016201D0 (no)	2001-12-18	Tienopyrimidiner som fosfodiesteraseinhibitorer
NO20014243D0 (no)	2001-08-31	Dihetero-substituerte metalloprotease inhibitorer
NO20021959L (no)	2002-05-29	Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
NO20016301D0 (no)	2001-12-21	Terapeutiske midler
DK1690853T3 (da)	2010-06-07	Omega-carboxyaryl-substituerede diphenylurinstoffer til anvendelse som raf-kinaseinhibitorer
SI1268481T1 (sl)	2008-06-30	Inhibitorji kinaze kot zdravila
IDP000027420A (id)	2001-12-20	Inhibitor-inhibitor kinase pirolotriazin